500 related articles for article (PubMed ID: 27000539)
21. A Two-Tiered In Vitro Approach to De-Risk Drug Candidates for Potential Bile Salt Export Pump Inhibition Liabilities in Drug Discovery.
Hafey MJ; Houle R; Tanis KQ; Knemeyer I; Shang J; Chen Q; Baudy A; Monroe J; Sistare FD; Evers R
Drug Metab Dispos; 2020 Nov; 48(11):1147-1160. PubMed ID: 32943412
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs.
Mita S; Suzuki H; Akita H; Hayashi H; Onuki R; Hofmann AF; Sugiyama Y
Drug Metab Dispos; 2006 Sep; 34(9):1575-81. PubMed ID: 16760228
[TBL] [Abstract][Full Text] [Related]
23. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.
Funk C; Ponelle C; Scheuermann G; Pantze M
Mol Pharmacol; 2001 Mar; 59(3):627-35. PubMed ID: 11179459
[TBL] [Abstract][Full Text] [Related]
24. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Morgan RE; van Staden CJ; Chen Y; Kalyanaraman N; Kalanzi J; Dunn RT; Afshari CA; Hamadeh HK
Toxicol Sci; 2013 Nov; 136(1):216-41. PubMed ID: 23956101
[TBL] [Abstract][Full Text] [Related]
25. Antibiotic-Induced Elevations of Plasma Bile Acids in Rats Independent of Bsep Inhibition.
Li Y; Hafey MJ; Duong H; Evers R; Cheon K; Holder DJ; Galijatovic-Idrizbegovic A; Sistare FD; Glaab WE
Toxicol Sci; 2017 May; 157(1):30-40. PubMed ID: 28108666
[TBL] [Abstract][Full Text] [Related]
26. Intravital Multiphoton Microscopy with Fluorescent Bile Salts in Rats as an In Vivo Biomarker for Hepatobiliary Transport Inhibition.
Ryan J; Morgan RE; Chen Y; Volak LP; Dunn RT; Dunn KW
Drug Metab Dispos; 2018 May; 46(5):704-718. PubMed ID: 29467212
[TBL] [Abstract][Full Text] [Related]
27. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions.
Fattinger K; Funk C; Pantze M; Weber C; Reichen J; Stieger B; Meier PJ
Clin Pharmacol Ther; 2001 Apr; 69(4):223-31. PubMed ID: 11309550
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles.
Zhang J; Doshi U; Suzuki A; Chang CW; Borlak J; Li AP; Tong W
Chem Biol Interact; 2016 Aug; 255():3-11. PubMed ID: 26581450
[TBL] [Abstract][Full Text] [Related]
29. Toward predicting drug-induced liver injury: parallel computational approaches to identify multidrug resistance protein 4 and bile salt export pump inhibitors.
Welch MA; Köck K; Urban TJ; Brouwer KL; Swaan PW
Drug Metab Dispos; 2015 May; 43(5):725-34. PubMed ID: 25735837
[TBL] [Abstract][Full Text] [Related]
30. Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).
Pedersen JM; Matsson P; Bergström CA; Hoogstraate J; Norén A; LeCluyse EL; Artursson P
Toxicol Sci; 2013 Dec; 136(2):328-43. PubMed ID: 24014644
[TBL] [Abstract][Full Text] [Related]
31. Contribution of high basolateral bile salt efflux to the lack of hepatotoxicity in rat in response to drugs inducing cholestasis in human.
Jemnitz K; Veres Z; Vereczkey L
Toxicol Sci; 2010 May; 115(1):80-8. PubMed ID: 20147439
[TBL] [Abstract][Full Text] [Related]
32. Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: mechanistic considerations beyond the direct inhibition of the bile salt export pump.
Rodrigues AD; Lai Y; Cvijic ME; Elkin LL; Zvyaga T; Soars MG
Drug Metab Dispos; 2014 Apr; 42(4):566-74. PubMed ID: 24115749
[TBL] [Abstract][Full Text] [Related]
33. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver.
Stieger B; Fattinger K; Madon J; Kullak-Ublick GA; Meier PJ
Gastroenterology; 2000 Feb; 118(2):422-30. PubMed ID: 10648470
[TBL] [Abstract][Full Text] [Related]
34. Transport by vesicles of glycine- and taurine-conjugated bile salts and taurolithocholate 3-sulfate: a comparison of human BSEP with rat Bsep.
Hayashi H; Takada T; Suzuki H; Onuki R; Hofmann AF; Sugiyama Y
Biochim Biophys Acta; 2005 Dec; 1738(1-3):54-62. PubMed ID: 16332456
[TBL] [Abstract][Full Text] [Related]
35. The C-DILI™ Assay: An Integrated In Vitro Approach to Predict Cholestatic Hepatotoxicity.
Jackson JP; Brouwer KR
Methods Mol Biol; 2019; 1981():75-85. PubMed ID: 31016648
[TBL] [Abstract][Full Text] [Related]
36. BSEP inhibition: in vitro screens to assess cholestatic potential of drugs.
Kis E; Ioja E; Rajnai Z; Jani M; Méhn D; Herédi-Szabó K; Krajcsi P
Toxicol In Vitro; 2012 Dec; 26(8):1294-9. PubMed ID: 22120137
[TBL] [Abstract][Full Text] [Related]
37. Hepatobiliary disposition in primary cultures of dog and monkey hepatocytes.
Rose KA; Kostrubsky V; Sahi J
Mol Pharm; 2006; 3(3):266-74. PubMed ID: 16749858
[TBL] [Abstract][Full Text] [Related]
38. Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.
Feng B; Xu JJ; Bi YA; Mireles R; Davidson R; Duignan DB; Campbell S; Kostrubsky VE; Dunn MC; Smith AR; Wang HF
Toxicol Sci; 2009 Apr; 108(2):492-500. PubMed ID: 19223659
[TBL] [Abstract][Full Text] [Related]
39. The role of bile salt export pump gene repression in drug-induced cholestatic liver toxicity.
Garzel B; Yang H; Zhang L; Huang SM; Polli JE; Wang H
Drug Metab Dispos; 2014 Mar; 42(3):318-22. PubMed ID: 24335466
[TBL] [Abstract][Full Text] [Related]
40. The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity.
Guo YX; Xu XF; Zhang QZ; Li C; Deng Y; Jiang P; He LY; Peng WX
Toxicol Mech Methods; 2015; 25(5):382-7. PubMed ID: 25886055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
